retatrutide type 2 diabetes trial nct Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 A new clinical trial from

Plain water is inadequate for ESD: insufficient conductivity higher diathermy settings required Isotonic saline (0.9% NaCl): electrolyte-rich conductive medium facilitates cutting, coagulation and vessel precoagulation ESGE 2023 guidelines explicitly endorse saline over water in immersion-assisted ESD SITE-PCM: especially powerful combination the pocket stabilises the dissection plane, SITE optimises optics, buoyancy and diathermy performance Asclepius tube: continuous drainage of excess saline without repeated through-the-scope suctioning Western cohort data (181 lesions, Royal Free): R0 92.3%, curative resection 90.6%, 93.4% under conscious sedation, 0.5% surgery rate Conclusion: SITE is not a competitor to conventional ESD it is a flexible adjunct, most valuable in fibrotic lesions, anatomically challenging segments, and for broadening access to ESD without general anaesthesia

Some people do very well with tirzepatide and achieve the weight loss results and improved blood sugar control they are looking for

Steve Small: Yeah, I didnt realize how undertreated it is

Future Outlook Older patients with skin laxity following weight loss are often marinating in real world solutions

[5] [11] Some sleep difficulties reported during trials may therefore reflect the underlying condition rather than a direct drug effect

While GLP-1s have proven life-changing for people with diabetes, obesity, and other medical conditions, using them for cosmetic weight loss has always seemed a little extreme to me, at least for noncelebrities whose very income doesnt hinge on fitting societys expectations of what a person should look like